Novavax | NVAX - Betriebsaufwand





Betriebsaufwand Veränderung Datum
Adma Biologics USD 64.2M 12.21M 2026-03
Agenus USD -221.22M 241.03M 2026-03
AstraZeneca USD 8.18B 4.35B 2026-03
BioCryst Pharmaceuticals USD -553.84M 700.01M 2026-03
Cassava Sciences USD 11.17M 2.38M 2026-03
Geron USD 52.07M 6.73M 2026-03
GlaxoSmithKline GBP 5.34B 1.85B 2026-03
MannKind USD 110.9M 8.74M 2026-03
Merck USD 18.17B 8.01B 2026-03
Minerva Neurosciences USD 4.52M 155.46K 2024-12
Moderna USD 1.78B 242M 2026-03
Novartis USD 9.29B 507M 2026-03
Novavax USD 126.2M 23.62M 2025-12
Pfizer USD 90.1B 77.19B 2026-03
Sanofi EUR 9.31B 1.2B 2026-03
Sarepta Therapeutics USD 372.37M 480.65M 2026-03
TG Therapeutics USD 170.12M 28.04M 2026-03